CA2295023A1 - Solutions contenant des azasteroides - Google Patents

Solutions contenant des azasteroides Download PDF

Info

Publication number
CA2295023A1
CA2295023A1 CA002295023A CA2295023A CA2295023A1 CA 2295023 A1 CA2295023 A1 CA 2295023A1 CA 002295023 A CA002295023 A CA 002295023A CA 2295023 A CA2295023 A CA 2295023A CA 2295023 A1 CA2295023 A1 CA 2295023A1
Authority
CA
Canada
Prior art keywords
solution
steroid
composition
aza
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295023A
Other languages
English (en)
Inventor
Alan Frank Parr
Michele Catherine Rizzolio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2295023A1 publication Critical patent/CA2295023A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle solution renfermant une quantité thérapeutiquement efficace d'un stéroïde aza pharmaceutiquement actif, un polyéthylène glycol et un propylène glycol. Dans un deuxième aspect, cette invention concerne une composition pharmaceutique renfermant la solution de l'invention. Enfin, dans un troisième aspect, cette invention concerne une capsule de gélatine remplie avec la composition de l'invention.
CA002295023A 1997-08-19 1998-08-17 Solutions contenant des azasteroides Abandoned CA2295023A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9717444.5 1997-08-19
GBGB9717444.5A GB9717444D0 (en) 1997-08-19 1997-08-19 Pharmaceutical composition
PCT/EP1998/005192 WO1999008684A2 (fr) 1997-08-19 1998-08-17 Solutions contenant des azasteroïdes

Publications (1)

Publication Number Publication Date
CA2295023A1 true CA2295023A1 (fr) 1999-02-25

Family

ID=10817633

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295023A Abandoned CA2295023A1 (fr) 1997-08-19 1998-08-17 Solutions contenant des azasteroides

Country Status (10)

Country Link
EP (1) EP1005346A2 (fr)
JP (1) JP2002511100A (fr)
KR (1) KR20010014079A (fr)
CN (1) CN1263466A (fr)
AU (1) AU8979698A (fr)
BR (1) BR9810285A (fr)
CA (1) CA2295023A1 (fr)
GB (1) GB9717444D0 (fr)
TR (1) TR199903211T2 (fr)
WO (1) WO1999008684A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
EP1704162A1 (fr) * 2004-01-02 2006-09-27 PharmaCon Forschung und Beratung GmbH Procede de production d'azasteroides insatures en position 1,2
EP2050436A1 (fr) 2007-12-21 2009-04-22 Siegfried Generics International AG Composition pharmaceutique qui comporte de la dutastéride
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
KR101055412B1 (ko) * 2010-11-19 2011-08-08 (주)비씨월드제약 두타스테라이드를 포함하는 자가유화 에멀젼 조성물 및 이의 제조방법
CN103169712B (zh) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 提高生物利用度的度他雄胺制剂及其制备方法
BR112014028602B1 (pt) * 2012-05-18 2023-10-24 Luoda Pharma Limited Formulação líquida não aquosa oralmente biodisponível para administração oral
CN103479595B (zh) * 2012-06-13 2015-08-26 成都国弘医药有限公司 一种含有度他雄胺的软胶囊
WO2014002015A1 (fr) 2012-06-25 2014-01-03 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant du dutastéride
CN103830201A (zh) * 2012-11-20 2014-06-04 重庆医药工业研究院有限责任公司 一种度他雄胺液体软胶囊
ES2555485T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
JP7017938B2 (ja) * 2018-01-15 2022-02-09 森下仁丹株式会社 ３－オキソ－４－アザアンドロスト－１－エン－１７－カルボン酸誘導体含有製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516768A (en) * 1990-03-16 1996-05-14 Smithkline Beecham Corporation Uncompetitive inhibition of steroid and 5α-reductose
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
JPH11513380A (ja) * 1995-09-27 1999-11-16 メルク エンド カンパニー インコーポレーテッド ５−αレダクターゼ阻害剤によるアンドロゲン性脱毛症の予防方法
WO1998025463A1 (fr) * 1996-12-09 1998-06-18 Merck & Co., Inc. Procedes et compositions permettant de prevenir et de traiter la perte osseuse

Also Published As

Publication number Publication date
WO1999008684A3 (fr) 1999-06-10
CN1263466A (zh) 2000-08-16
JP2002511100A (ja) 2002-04-09
WO1999008684A2 (fr) 1999-02-25
EP1005346A2 (fr) 2000-06-07
AU8979698A (en) 1999-03-08
GB9717444D0 (en) 1997-10-22
KR20010014079A (ko) 2001-02-26
BR9810285A (pt) 2000-09-12
TR199903211T2 (xx) 2000-04-21

Similar Documents

Publication Publication Date Title
TWI490216B (zh) 用作ｃ型肝炎病毒蛋白酶抑制劑之醫藥組合物
KR100425755B1 (ko) 이트라코나졸을 함유하는 조성물 및 그 제조방법
CA2295023A1 (fr) Solutions contenant des azasteroides
WO2004054540A3 (fr) Formulations solides a ecoulement facile presentant une biodisponibilite amelioree de medicaments faiblement solubles dans l'eau et leur procede de fabrication
EP2468262A1 (fr) Composition pharmaceutique contenant de la dutastéride
CA2804635A1 (fr) Formulations de rifaximine et utilisations correspondantes
JP6276756B2 (ja) １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
CA2295016A1 (fr) Composition pharmaceutique
EP2934591B1 (fr) Forme pharmaceutique orale solide de dérivé de testostérone
KR20040101300A (ko) 경질 쉘 캡슐용 이부프로펜 용액
KR101745425B1 (ko) 두타스테라이드 및 타다라필을 포함하는 경구용 복합제제 에멀젼 조성물 및 그 제조방법
EP3854384A1 (fr) Formulation pharmaceutique comprenant de l'acétate d'abiratérone
MXPA99011970A (en) Pharmaceutical composition
MXPA99011995A (en) Solutions containing azasteroids
CA3050347C (fr) Capsules molles contenant de l'hydroxypropyl-beta-cyclodextrine d'une grande stabilite
AU7615000A (en) Vasopressin antagonist formulation and process
MX2008002251A (en) Pharmaceutical formulation with high stability and dissolution and manufacturing process
KR20050121497A (ko) 이트라코나졸의 경구투여용 조성물 및 그 제조방법

Legal Events

Date Code Title Description
FZDE Dead